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signiﬁcantly thickened compared to sham knee joints at 8 weeks after
surgery. In contrast, strain 6 mice showed thinning at all time points
(Figure 1B). Strain 6 mice showed signiﬁcantly lower bone volume
fraction at all time points, while in strain 33 mice bone volume was
lower only at 4 weeks and reversed from 4 to 8 weeks. Trabecular
thickness was less in strain 6 mice at all time points, but only at 4 weeks
in strain 33 mice with thickening at 8 weeks. The trabecular connective
density, which calculates the number of trabecular bone connections,
showed strain 33 mice looses trabecular bone at 4 weeks and thickens
by 8 weeks after surgery, while trabecular bone loss was observed in all
time points in strain 6 mice.
Conclusions: Strain 33 mice, which have poor healing ability for soft
tissues like ear hole, demonstrated a natural history of OA development:
they initially have bone loss, then cartilage loss followed by bone sclerosis
in the late stage of OA. In contrast, strain 6 mice, which have a good
healing ability in tissue, were protected against OA and showed bone
loss in all time points. These results suggest that cartilage and bone
changes associated with OA development are linked each other and
suggest that cartilage loss leads to subchondral bone thickening. In other
studies currently underway in our laboratory, we have found that strain
6 can repair a full thickness cartilage injury, while strain 33 cannot repair
its cartilage (Table 1). Therefore, our studies demonstrate a signiﬁcant
correlation between ear punch healing, cartilage repair and resistance to
OA in these genetic strains of mice.
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ORAL CALCITONIN DEMONSTRATED SYMPTOM-MODIFYING EFFICACY
AND INCREASED CARTILAGE VOLUME: RESULTS FROM A 2-YEAR
PHASE 3 TRIAL IN PATIENTS WITH OSTEOARTHRITIS OF THE KNEE
M.A. Karsdal1, P. Alexandersen2, M.R. John3, J. Loefﬂer3, M. Arnold3,
M. Azria3, I. Byrjalsen1, B.J. Riis1, C. Christiansen1, CCBR 2301
Investigators. 1Nordic BioSci., Herlev, Denmark; 2Orla Lehmannsgade, Vejle,
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Purpose: To evaluate the symptom- and structure-modifying efﬁcacy and
safety of oral salmon calcitonin (oCT) formulated with a 5-CNAC carrier
(a molecule based on Eligen® technology from Emisphere), in patients
with moderate to severe knee pain and structural damages classiﬁed as
Kellgren-Lawrence 2–3 due to osteoarthritis (OA).
Methods: A total of 1169 men and women aged 50–80 years with
a mean BMI of 28.9 kg/m2 who had painful OA of the knee with
structural manifestations were enrolled in this multi-center, double-
blind, randomized placebo-controlled study. Patients received (1:1) oCT
0.8mg twice daily or placebo for 24 months; rescue medication was
allowed in both arms. The primary efﬁcacy endpoints were joint-space
width (JSW), WOMAC pain and function visual analogue scale scores after
24 months in the signal knee. Secondary endpoints included but were not
limited to WOMAC stiffness, patient and physician global assessments,
and knee cartilage degradation. Safety endpoints were adverse events
(AEs) and tolerability.
Results: Baseline values were well matched between the two groups.
In ITT analysis at 24 months, oCT treatment did not have an effect
on JSW (p=0.97; progression was −0.2mm in both groups). However,
oCT increased cartilage volume by a mean 4.8% (0.73%) [vs 2.5% (0.61%)
in placebo group, p = 0.012]. Furthermore, oCT resulted in signiﬁcant
changes (vs placebo) in WOMAC pain [−115.7 (4.9) vs −94.9 (4.8) mm;
p=0.002], function [−338.7 (16.7) vs −283.0 (15.8) mm; p=0.013] (see
Figure) and stiffness [−44.1 (2.2) vs −32.6 (2.1) mm; p < 0.001] scores
(numbers in parentheses are standard errors). Improvement was also
obtained in the oCT group (vs placebo) in VAS 24 hour pain (p = 0.018),
patient global assessment (p =0.008) and physician global assessment
(p = 0.014). The discontinuation rate was 33% for oCT vs 23% for placebo
treatment. Drug-related AE discontinuations occurred in 19.5% oCT group
(vs 5.8% in placebo group), mostly happening early in the oCT group
then parallel to placebo. The most common AEs in the oCT group (vs
placebo) were hot ﬂush (17.8 vs 4.1%), nausea (14 vs 3.1%), dyspepsia
(10.1 vs 4.5%) and diarrhoea (9.6 vs 4.3%), and accounted for most
discontinuations. Immunogenicity was noted in 17.4% (oCT) vs 1.6%
(placebo) at 24 months.
Figure: Select efﬁcacy variables: mean changes over two years.
Conclusions: Twice daily oCT over 2 years resulted in a signiﬁcant
symptom-modifying efﬁcacy in patients with painful knee OA as assessed
by WOMAC pain, physical function, and stiffness scores. Although
improvement on the primary endpoint of JSW was not reached, there
was an increase in cartilage volume vs placebo indicating some structure-
modifying efﬁcacy. Safety and tolerability of oCT was largely in line with
previous clinical experience with calcitonins.
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INTRAARTICULARLY USING SINGLE OR MULTIPLE ASCENDING
DOSES IN PATIENTS WITH PRIMARY KNEE OSTEOARTHRITIS (OA),
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Purpose: There are no disease-modifying OA drugs (DMOAD) – a
continuing unmet need. In OA, levels of growth factors (key regulators
of chondrocyte activity) decline with age, thus reducing cartilage
maintenance and ability to resist mechanical stress. Fibroblast growth
factor 18 (FGF18) is a chondrogenic factor that promotes chondrocyte
proliferation and stabilization of the ’healthy’ anabolic chondrocyte
phenotype. This Proof of Concept (PoC) study in OA patients evaluated
the effects of intraarticular (i.a.) rhFGF18 injection after single ascending
dose (SAD) and multiple ascending dose (MAD) regimens.
Methods: Eligible patients were ≥40 y with symptomatic primary
femorotibial OA of the target knee and radiological disease (Kellgren-
Lawrence grades 2 or 3), with no major knee surgery planned for
≥1 y after ﬁrst injection of study drug; stable oral OA treatments
were permitted. Patients received rhFGF18 or placebo, randomized 3:1
per cohort. Study drug was injected in 10mg, 30mg, or 100mg doses
either once (SAD) or once weekly for 3 weeks in 2 treatment cycles
(MAD). Follow-up and safety reviews occurred weekly over the 4 weeks
postinjection (both cohorts) and at weeks 8, 13, 14, 15, 17, 26, 39
and 52 postinjection (MAD cohorts). Efﬁcacy (MAD cohorts) included
assessment of knee cartilage in selected regions of interest by MRI exam,
joint space width (JSW) of target knee on X-ray, and function and pain
in target knee (WOMAC scores). MRI was performed with coronal SPGR
sequences at baseline, 12, 26, and 52 weeks; X-ray was performed in the
semiﬂexed position at baseline and 52 weeks. All cohorts were assessed
for local and systemic safety. SAD cohorts were assessed for systemic
exposure to rhFGF18.
Results: In SAD cohorts, 18 patients received rhFGF18; 6 received
placebo. In MAD cohorts, 126 received rhFGF18; 42 received placebo.
Age range was 41.4–84.9 y; the BMI range was 15.6–49.0 kg/m 2. As
measured in MAD cohorts, there was a signiﬁcant dose-dependent
anabolic effect of rhFGF18 on cartilage: for the total femorotibial cartilage
volume at 12 months, compared with placebo (−112.69±470.16mm3)
cartilage loss slowed with the lowest dose (−45.20±1117.3mm3), stopped
with the intermediate dose (−1.09±189.93mm3) and reversed with
the highest dose (52.68±175.7mm3; overall p-value=0.0251). Effects
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were most pronounced in the lateral compartment. Mean reduction
in JSW was lower with rhFGF18 than with placebo in the lateral
compartment, where an increase in JSW was observed in the high-
dose group (10mg: −0.02±0.86, 30mg: 0.00±0.73, 100mg: 0.34±0.90,
placebo: −0.18±0.74, overall p-value = 0.0077). Strong improvements in
WOMAC scores vs. baseline were observed in all groups: function scores
10mg: −15.76±13.72, 30mg: −12.12±12.06, 100mg: −11.28±15.30, placebo:
−17.02±13.56, overall p-value=0.0322; pain scores 10mg: −4.10±5.11,
30mg: −3.54±3.67, 100mg: −2.87±4.76, placebo: −5.56±4.17, overall
p-value=0.0044. However, no improvement of active vs. placebo was
demonstrated. No local or systemic safety signals were observed.
Acute inﬂammatory reactions were slightly more common with active
treatment, but this was not dose-dependent; no increase in knee pain
and no safety issues emerged. Serum FGF18 levels (SAD cohorts) were
below the lower limit of quantiﬁcation at all time points in all subjects.
Conclusions: In this PoC study, i.a. injection of rhFGF18 was associated
with a signiﬁcant dose-dependent improvement in total femorotibial
cartilage volume and JSW. No local or systemic safety issues emerged
and treatment was well tolerated. All patients on rhFGF18 experienced
symptom improvement vs. baseline, with a placebo response higher than
active treatment. rhFGF18 is a promising DMOAD that warrants further
long-term clinical investigation.
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ROLE OF VITAMIN D IN OSTEOARTHRITIS KNEE: A SIX MONTH
DOUBLE BLIND, RANDOMIZED, PLACEBO CONTROL TRIAL
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S. Avasthi3. 1CSM Med. Univ., Lucknow, India; 2SGPGIMS, Lucknow, India;
3GSVM Med. Coll., kanpur, India
Purpose: There is a putative role of vitamin D in osteoarthritis (OA)
based on animal, epidemiological and human clinical studies. Short term
clinical studies suggest beneﬁcial inﬂuence of vitamin D on local changes
in the bone which probably accounts for diminished pain experienced in
knee OA (KOA). Inadequate sunlight exposure and lower serum levels of
25(OH)D appears to be associated with an increased risk for progression
of OA knee. Some chronic analgesic users with OA knee were more
likely to be in lower categories of 25(OH) D compared to women with
asymptomatic OA. On the basis of above background this study was
planned to assess the effect of vitamin D on the progression of disease
Methods: A six month, double blind, randomized and placebo controlled
trial of vitamin D, in vitamin D insufﬁcient OA knee subjects (serum
25 (OH) D levels <50nmol/L) was conducted. 150 subjects of primary
OA knee, diagnosed by ACR guidelines, were subjected to personal
interview to determine their vitamin D intake (by 3 day dietary recall and
food frequency table) and the daily sunlight exposure in hours. Serum
levels of calcium, phosphorus, alkaline phosphatase and 25(OH) D were
measured to determine their vitamin D proﬁle. We identiﬁed 64 vitamin
D insufﬁcient subjects out of 150 primary OA knee patients. These were
randomized by random allocation table for intervention. In cases a bolus
dose of calciferol in 60,000 IU/day for 10 days followed by 60,000
IU/month for six months was administered and in controls a placebo in
the same schedules and durations was given. Primary outcome measures
were clinical WOMAC scores (pain, stiffness and physical function) and
VAS for knee pain. Secondary outcome measures were radiological
features (joint space width, osteophyte scores, subchondral sclerosis
scores and tibio femoral alignment) and KL grades. The serum levels
of vitamin D were assessed by using Enzyme Linked Immunosorbent
Assay (ELISA) and calcium /phosphorus/alkaline phosphatase by UV end
point method. Statistical analysis was performed on an intension to treat
basis.
Results: There was no signiﬁcant baseline difference of age, sex, analgesic
frequency, dietary vitamin D intake, serum levels of vitamin D, calcium,
phosphorus, alkaline phosphatase and in clinical and radiological scores
between the cases and controls. BMI (25.96 vs 25.65, p = 0.75) and pain
(10.94 vs 10.64, p = 0.66) was higher in the placebo group although
difference was not statistically signiﬁcant. There was no signiﬁcant
difference in radiological features and KL grades from baseline and at
6 months in both the groups.At six months, both the groups had an
improvement in WOMAC and VAS pain scores but vitamin D showed
beneﬁt over placebo from baseline (p < 0.01); for WOMAC physical
function vitamin D group showed signiﬁcant improvement over placebo
which remained same as their base line levels.
Conclusions: Although a long term study is being recommended to
establish radiological progression, if any, this short term randomize
placebo control trial yields a beneﬁcial effect of vitamin D in pain and
physical function outcomes in KOA.Vitamin D intake was beneﬁcial in
symptomatic improvement of KOA.
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STRUCTURAL TISSUE CHANGES AND PROLONGED CLINICAL
IMPROVEMENT BY JOINT DISTRACTION IN TREATMENT OF
END-STAGE KNEE OSTEOARTHRITIS; THE 2 YEARS FOLLOW-UP
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Purpose: Knee joint distraction (KJD) is a new treatment for end-stage
osteoarthritis (OA) of the knee that temporarily unloads the femorotibial
cartilage and subchondral bone. This technique was previously shown to
be clinically effective at 1 year follow-up. Clinical improvement coincided
with the signiﬁcant increase of joint space width and cartilage thickness,
decrease in denuded bone areas, and decrease of bone sclerosis. The
current study provides 2 year follow-up results on the effect of KJD.
Methods: The open, uncontrolled study included 20 patients (age
49±6 years; 11 females) with end-stage knee OA, considered for total
knee replacement. Patients were treated with KJD for 2 months. The
study was approved by the medical ethical committee (METC) of the
University of Utrecht and all patients gave written informed consent.
Two monotubes with internal coil springs were placed parallel on the
medial and lateral side, bridging the knee joint, creating a distance
between both cartilage surfaces of 5mm, conﬁrmed by X-ray. Patients
were encouraged to load the knee during distraction, in order to attain
intermittent intra-articular ﬂuid pressures. After 2 months, tubes and
pins were removed.
The primary clinical outcome parameter was pain and function by
use of the ‘Western Ontario McMasters University Index’ (WOMAC)
questionnaire, with a visual analoge pain score (VAS) as secondary
outcome. The primary structural outcome was minimal joint space width
(JSW) on semi-ﬂexed, anterior-posterior, weight bearing radiographs
(Buckland-Wright, MTP) analyzed by digital interactive computer
analysis (KIDA). Secondary structural outcomes were quantitative MRI
parameters of cartilage morphology, analyzed by Chondrometrics Gmbh
(Ainring, Germany). Additionally, biomarkers for synthesis (sPIIANP) and
breakdown (uCTXII) of collagen type II were evaluated.
Results: Total WOMAC score increased from 45%±3.6 at baseline to
78%±4.8 at 2 years (p < 0.000) and the VAS pain score decreased from
73±2.1 at baseline to 28±6.0mm at 2 years (p< 0.000). The clinical
improvement coincided with structural tissue changes: the minimum
JSW increased from 1.0±0.3 to 1.8±0.3mm (p < 0.03) at 2 years;
quantitative MRI analysis corroborated this result by an increase in
cartilage thickness over total subchondral bone area (ThCtAB) of the
most affected compartment (from 2.4±0.1 at baseline to 2.8±0.1mm at
2 years; p < 0.05) and a decrease of the percentage of subchondral bone
area that was denuded (dABp: change from 22±5 at baseline to 8±2% at
2 years; p < 0.004). MRI and X-ray changes were moderately correlated
(r = 0.67 p < 0.000).
Biomarker analysis shows that, directly after treatment from 6 months
follow-up to 2 years, the average change in the ratio of PIIANP / CTXII
changed in favor of collagen type II synthesis (p < 0.003).
Conclusions: Joint distraction results in signiﬁcant improvement in the
clinical (pain) and structural (cartilage) status in end-stage knee OA
which is sustained for at least 2 years. We have shown previously
that this clinical improvement is seen already one month after KJD
treatment.
MRIs suggest an increase in cartilage thickness and covering of denuded
areas in comparison with baseline values. The mechanical competence of
the formed tissue is suggested by increased JSW of weight-bearing X-ray,
and the hyaline nature by collagen type II biomarker analysis. Structural
changes over 1 year were slightly greater compared with those over
2 years follow-up suggesting that the main therapeutic effect occurs in
the ﬁrst year, and is maintained in the 2nd year. At present, distraction
therapy appears to be the ﬁrst treatment that can reverse cartilage
damage in end-stage knee osteoarthritis accompanied by signiﬁcant
clinical improvement.
